CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

Depression disorder is one of the most serious mental illnesses in the world. Escitalopram is the essential first-line medication for depression disorder. It is the substrate of hepatic cytochrome P450 (CYP) enzyme CYP2C19 with high polymorphism. The effect of CYP2C19 on pharmacokinetics and pharmac...

Full description

Bibliographic Details
Main Authors: Xinyi Huang, Chao Li, Chaopeng Li, Zhenyu Li, Xiaohui Li, Jianwei Liao, Tai Rao, Lulu Chen, Lichen Gao, Dongsheng Ouyang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
selective serotonin reuptake inhibitor1
escitalopram2
pharmacogenomics3
individualized treatment4
clinical trials
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.730461/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.730461/full

Similar Items